Under the terms of the agreement, TAP will be responsible for promoting Famvir to the Obstetrician and Gynecology medical community.
Famvir is the first and only oral antiviral approved to treat recurrent genital herpes and cold sores with just a single day of therapy. Famvir is also indicated for the treatment of recurrent genital herpes and cold sores in HIV-infected patients, and for the treatment of shingles.
Famvir has been shown to significantly reduce the time to healing of non-aborted lesions, as well as time to resolution of studied symptoms, such as pain and burning, in patients by almost two days.
Novartis commented they hoped the alliance would make the drug Famvir more accessible for physicians and patients.
Specific terms of the agreement were not disclosed.